Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients

Blood Cancer J. 2016 Aug 26;6(8):e464. doi: 10.1038/bcj.2016.76.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Case-Control Studies
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Humans
  • Lymphoma, Follicular / diagnosis*
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / genetics*
  • Lymphoma, Follicular / mortality
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide*
  • Prednisone / therapeutic use
  • Prognosis
  • Rituximab
  • Survival Analysis
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / genetics*
  • Vincristine / therapeutic use

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol